Cargando…
Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239505/ https://www.ncbi.nlm.nih.gov/pubmed/32436148 http://dx.doi.org/10.1007/s10549-020-05674-7 |
| _version_ | 1783536704255164416 |
|---|---|
| author | O’Shaughnessy, Joyce |
| author_facet | O’Shaughnessy, Joyce |
| author_sort | O’Shaughnessy, Joyce |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7239505 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72395052020-05-20 Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy O’Shaughnessy, Joyce Breast Cancer Res Treat Letter to the Editor Springer US 2020-05-20 2020 /pmc/articles/PMC7239505/ /pubmed/32436148 http://dx.doi.org/10.1007/s10549-020-05674-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor O’Shaughnessy, Joyce Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title | Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title_full | Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title_fullStr | Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title_full_unstemmed | Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title_short | Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| title_sort | treatment options for patients with hr+/her2− advanced breast cancer during the covid-19 pandemic: dose reduction of ribociclib does not diminish efficacy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239505/ https://www.ncbi.nlm.nih.gov/pubmed/32436148 http://dx.doi.org/10.1007/s10549-020-05674-7 |
| work_keys_str_mv | AT oshaughnessyjoyce treatmentoptionsforpatientswithhrher2advancedbreastcancerduringthecovid19pandemicdosereductionofribociclibdoesnotdiminishefficacy |